Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.
Targeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. Our products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.
CRISPR-Cas3 drives in-vivo selection of TBX Cargo to generate a robust and durable therapeutic effect
Manipulating specific activities in targeted microbiome bacteria
Oral delivery of human biotherapeutics
Precise targeting with no disruption of the natural microbiome
Innovative unified core system for phage cocktail production